A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.

Trial Details

NCT ID

NCT07283705

Phase

PHASE2

Sponsor

M.D. Anderson Cancer Center

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

BMS-986504
Gemcitabine
Nab-paclitaxel
mFOLFIRINOX

Locations (sample)

Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

Eligibility Criteria
Age ≥18 years.
Homozygous MTAP deletion detected by NGS. Test can be performed on an archival tissue collected within 6 months from study enrollment and on blood …
ECOG performance status 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →